Potential incretins

L. T. Shuster, V. L W Go, R. A. Rizza, P. C. O'Brien, F. J. Service

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A greater plasma concentration of insulin after isoglycemic enteral than after parenteral administration of glucose is called the incretin effect. The primary mediator of this effect, gastric inhibitory polypeptide, may not account for the complete manifestation of this phenomenon. We evaluated other gastroenteric polypeptides with respect to a differential response to oral ingestion of glucose and intravenous administration of glucose at rates that achieved arterial plasma glucose concentrations matched to those from orally administered glucose. Gastrin, peptide histidine methionine, peptide YY, and neurotensin showed increases in plasma concentrations in response to oral ingestion of glucose but not to intravenous administration of glucose. Vasoactive intestinal polypeptide showed no increased concentration in response to either oral or intravenous administration of glucose. The differential responses to orally and intravenously administered glucose noted in the former gastroenteric polypeptides qualifies them as potential mediators of the incretin effect.

Original languageEnglish (US)
Pages (from-to)794-800
Number of pages7
JournalMayo Clinic Proceedings
Volume63
Issue number8
StatePublished - 1988

Fingerprint

Incretins
Glucose
Intravenous Administration
Eating
Peptide PHI
Gastric Inhibitory Polypeptide
Peptide YY
Neurotensin
Peptides
Vasoactive Intestinal Peptide
Gastrins
Small Intestine
Oral Administration
Insulin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Shuster, L. T., Go, V. L. W., Rizza, R. A., O'Brien, P. C., & Service, F. J. (1988). Potential incretins. Mayo Clinic Proceedings, 63(8), 794-800.

Potential incretins. / Shuster, L. T.; Go, V. L W; Rizza, R. A.; O'Brien, P. C.; Service, F. J.

In: Mayo Clinic Proceedings, Vol. 63, No. 8, 1988, p. 794-800.

Research output: Contribution to journalArticle

Shuster, LT, Go, VLW, Rizza, RA, O'Brien, PC & Service, FJ 1988, 'Potential incretins', Mayo Clinic Proceedings, vol. 63, no. 8, pp. 794-800.
Shuster LT, Go VLW, Rizza RA, O'Brien PC, Service FJ. Potential incretins. Mayo Clinic Proceedings. 1988;63(8):794-800.
Shuster, L. T. ; Go, V. L W ; Rizza, R. A. ; O'Brien, P. C. ; Service, F. J. / Potential incretins. In: Mayo Clinic Proceedings. 1988 ; Vol. 63, No. 8. pp. 794-800.
@article{9f7140dbefe1430295119fc49cbf7af3,
title = "Potential incretins",
abstract = "A greater plasma concentration of insulin after isoglycemic enteral than after parenteral administration of glucose is called the incretin effect. The primary mediator of this effect, gastric inhibitory polypeptide, may not account for the complete manifestation of this phenomenon. We evaluated other gastroenteric polypeptides with respect to a differential response to oral ingestion of glucose and intravenous administration of glucose at rates that achieved arterial plasma glucose concentrations matched to those from orally administered glucose. Gastrin, peptide histidine methionine, peptide YY, and neurotensin showed increases in plasma concentrations in response to oral ingestion of glucose but not to intravenous administration of glucose. Vasoactive intestinal polypeptide showed no increased concentration in response to either oral or intravenous administration of glucose. The differential responses to orally and intravenously administered glucose noted in the former gastroenteric polypeptides qualifies them as potential mediators of the incretin effect.",
author = "Shuster, {L. T.} and Go, {V. L W} and Rizza, {R. A.} and O'Brien, {P. C.} and Service, {F. J.}",
year = "1988",
language = "English (US)",
volume = "63",
pages = "794--800",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Potential incretins

AU - Shuster, L. T.

AU - Go, V. L W

AU - Rizza, R. A.

AU - O'Brien, P. C.

AU - Service, F. J.

PY - 1988

Y1 - 1988

N2 - A greater plasma concentration of insulin after isoglycemic enteral than after parenteral administration of glucose is called the incretin effect. The primary mediator of this effect, gastric inhibitory polypeptide, may not account for the complete manifestation of this phenomenon. We evaluated other gastroenteric polypeptides with respect to a differential response to oral ingestion of glucose and intravenous administration of glucose at rates that achieved arterial plasma glucose concentrations matched to those from orally administered glucose. Gastrin, peptide histidine methionine, peptide YY, and neurotensin showed increases in plasma concentrations in response to oral ingestion of glucose but not to intravenous administration of glucose. Vasoactive intestinal polypeptide showed no increased concentration in response to either oral or intravenous administration of glucose. The differential responses to orally and intravenously administered glucose noted in the former gastroenteric polypeptides qualifies them as potential mediators of the incretin effect.

AB - A greater plasma concentration of insulin after isoglycemic enteral than after parenteral administration of glucose is called the incretin effect. The primary mediator of this effect, gastric inhibitory polypeptide, may not account for the complete manifestation of this phenomenon. We evaluated other gastroenteric polypeptides with respect to a differential response to oral ingestion of glucose and intravenous administration of glucose at rates that achieved arterial plasma glucose concentrations matched to those from orally administered glucose. Gastrin, peptide histidine methionine, peptide YY, and neurotensin showed increases in plasma concentrations in response to oral ingestion of glucose but not to intravenous administration of glucose. Vasoactive intestinal polypeptide showed no increased concentration in response to either oral or intravenous administration of glucose. The differential responses to orally and intravenously administered glucose noted in the former gastroenteric polypeptides qualifies them as potential mediators of the incretin effect.

UR - http://www.scopus.com/inward/record.url?scp=0023788439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023788439&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 794

EP - 800

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -